OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
Glutathione, often called the master antioxidant, is a powerful molecule that our bodies produce naturally, tirelessly working to fight oxidative stress, detoxify cells, and promote glowing skin
Tirzepatide (Zepbound) in the multi-dose KwikPen only
AMPs) and activates myeloid-derived suppressor cells (MDSCs), suppressing immune function
Benefits Modulates slow-wave (delta) sleep architecture: DSIP was originally identified in studies examining delta-wave activity during deep sleep phases
GHK-Cu reduces pain and anxiety